Karolinska has reported that Xspray Microparticles has launched a GMP production facility in Malmo, Sweden. In addition to offering particle development and characterization services, XSpray can now provide customers with drug particles and powders for use in their clinical studies.
XSpray’s RightSize Particle Manufacturing is a solution for pharmaceutical particle development and production, based on supercritical fluid technology.
Reportedly, the new GMP facility has been developed in collaboration with Galenica. Manufacturing will be carried out by Galenica at the company’s GMP suites in Malmo.
Conny Bogentoft, CEO of Karolinska, said: “We are extremely pleased with the development of this technology. The ability to produce GMP material is an important step both for XSpray and for Karolinska. It will enable this solution for pharmaceutical particle production to benefit other companies within our portfolio as well as external customers. Currently we have twelve companies with ongoing clinical trials, seven in Phase II and five in Phase I, and the need for high quality GMP material is increasing as our portfolio matures.”